Alpha 2.0
Login Register
» Articles » PMID: 36337312

Oncology and Reproductive Outcomes over 16 Years of Malignant Ovarian Germ Cell Tumors Treated by Fertility Sparing Surgery

Overview
Journal World J Clin Oncol
Publisher Baishideng Publishing Group
Specialty Oncology
Date 2022 Nov 7
PMID 36337312
Authors
Muangloei Rungoutok
Prapaporn Suprasert
Affiliations
Soon will be listed here.
Abstract

Background: Malignant ovarian germ cell tumors (MOGCT) are rare and frequently occur in women of young and reproductive age and the oncologic and reproductive outcomes after fertility-sparing surgery (FSS) for this disease are still limited.

Aim: To evaluate the oncology and reproductive outcomes of MOGCT patients who underwent FSS.

Methods: All MOGCT patients who underwent FSS defined as the operation with a preserved uterus and at least one side of the ovary at our institute between January 2005 and December 2020 were retrospectively reviewed.

Results: Sixty-two patients were recruited for this study. The median age was 22 years old and over 77% were nulliparous. The three most common histology findings were immature teratoma (32.2%), dysgerminoma (24.2%), and yolk sac tumor (24.2%). The distribution of stage was as follows; Stage I, 74.8%; stage II, 9.7%; stage III, 11.3%; and stage IV, 4.8%. Forty-three (67.7%) patients received adjuvant chemotherapy. With a median follow-up time of 96.3 mo, the 10-year progression-free survival and overall survival were 82.4% and 91%, respectively. For reproductive outcomes, of 43 patients who received adjuvant chemotherapy, 18 (41.9%) had normal menstruation, and 17 (39.5%) resumed menstruation with a median time of 4 mo. Of about 14 patients who desired to conceive, four were pregnant and delivered good outcomes. Only one case was aborted. Therefore, the successful pregnancy rate was 28.6.

Conclusion: The oncology and reproductive outcomes of MOGCT treated by FSS are excellent. Many patients show a long survival time with normal menstruation. However, the obstetric outcome is not quite satisfactory.

Citing Articles

Spontaneous pregnancy after fertility-sparing surgery and adjuvant chemotherapy for advanced pure dysgerminoma: A case report.

Goc G, Goc A, Kastrati G, Baftiu D, Kurshumliu F Clin Case Rep. 2024; 12(6):e9020.

PMID: 38827934 PMC: 11139637. DOI: 10.1002/ccr3.9020.

References
1.
Beiner M, Gotlieb W, Korach Y, Shrim A, Stockheim D, Segal Y . Cystectomy for immature teratoma of the ovary. Gynecol Oncol. 2004; 93(2):381-4. DOI: 10.1016/j.ygyno.2004.01.034. View
2.
Brown J, Friedlander M, Backes F, Harter P, OConnor D, de La Motte Rouge T . Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S48-54. DOI: 10.1097/IGC.0000000000000223. View
3.
Mikus M, Benco N, Matak L, Planinic P, Coric M, Lovric H . Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center. Arch Gynecol Obstet. 2020; 301(5):1227-1233. DOI: 10.1007/s00404-020-05522-5. View
4.
Turkmen O, Karalok A, Basaran D, Comert Kimyon G, Tasci T, Ureyen I . Fertility-Sparing Surgery Should Be the Standard Treatment in Patients with Malignant Ovarian Germ Cell Tumors. J Adolesc Young Adult Oncol. 2017; 6(2):270-276. DOI: 10.1089/jayao.2016.0086. View
5.
Williams S, Blessing J, Liao S, Ball H, Hanjani P . Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994; 12(4):701-6. DOI: 10.1200/JCO.1994.12.4.701. View